Filing Flows › Celldex Therapeutics (CLDX) › Q2 2026 › vs Q2 2025
Celldex Therapeutics (CLDX) Q2 2026 vs Q2 2025 (year over year)
Celldex Therapeutics's revenue fell $708K (-97%) from $730K in Q2 2025 to $22K in Q2 2026. The biggest changes: Contracts and grants −$708K (-98%); Product development and licensing agreements +$0 (0%).
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Contracts and grants | $15K | $723K | −$708K | -98% |
| Product development and licensing agreements | $7K | $7K | $0 | 0% |
| Revenue | $22K | $730K | −$708K | -97% |
| Other income, net | $7.1M | $7.3M | −$137K | -2% |
| Net loss | $73.5M | $56.6M | $16.9M | +30% |
| Costs & expenses | $80.6M | $64.6M | $16.1M | +25% |
| Operating costs | $80.6M | $64.6M | $16.1M | +25% |
| Research & development | $67.5M | $54.2M | $13.3M | +25% |
| General & admin | $13.1M | $10.4M | $2.7M | +26% |
| Operating cash sources | $73.5M | $56.6M | $16.9M | +30% |
| Depreciation & amortization | $902K | $873K | $29K | +3% |
| Share-based compensation | $8.4M | $9.2M | −$783K | -9% |
| Working capital & other | $6.8M | $2.5M | $4.3M | +168% |
| Cash used in operations | $57.4M | $44.0M | $13.4M | +30% |
| Net loss absorbed | $73.5M | $56.6M | $16.9M | +30% |
Questions
How much did Celldex Therapeutics's revenue grow year over year in Q2 2026?
Celldex Therapeutics's revenue fell $708K (-97%) from $730K in Q2 2025 to $22K in Q2 2026.
What drove Celldex Therapeutics's revenue change in Q2 2026?
Contracts and grants −$708K (-98%); Product development and licensing agreements +$0 (0%).